Chemotherapeutic effects of compound 593A (NSC-135758) on mouse leukemias and some transplanted animal tumors.
D000477:Alkylating Agents / Q000494:pharmacology; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use* / Q000633:toxicity; D001201:Ascites / Q000188:drug therapy; D002279:Carcinoma 256, Walker / Q000188:drug therapy; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D004351:Drug Resistance; D007939:Leukemia L1210 / Q000188:drug therapy; D007942:Leukemia, Experimental / Q000188:drug therapy*; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D014184:Transplantation, Homologous
D000477:Alkylating Agents; D000903:Antibiotics, Antineoplastic; D010879:Piperazines; D010880:Piperidines; C003905:3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione; D015122:Mercaptopurine; D008727:Methotrexate